HVEM & LIGHT Immune Checkpoint Pathway

HVEM & LIGHT Immune Checkpoint Pathway: Description

TNFSF14 / LIGHT / CD258, whose name is derived from homologous to lymphotoxins, exhibits inducible expression, and competes with herpes simplex virus (HSV) glycoprotein D for herpesvirus entry mediator (HVEM / TNFRSF14), a receptor expressed by T lymphocytes, is a recently identified member of the human and mouse TNF superfamily. TNFSF14 / LIGHT / CD258 is a 29-kD type II transmembrane protein produced by activated T cells, as well as monocytes and granulocytes, and immature DCs. Apart from its receptor on T cells, HVEM / TNFRSF14, TNFSF14 / LIGHT / CD258 binds to the lymphotoxin β receptor (LTβR) on stromal cells, and the DcR3/TR6 soluble protein.

In vitro, HVEM/LIGHT immune checkpoint pathway induces potent CD28-independent costimulatory activity, leading to NF-κB activation, production of IFN-γ and other cytokines, and T cell proliferation in response to allogeneic DCs. In vivo blockade studies show HVEM/LIGHT immune checkpoint pathway is involved in promotion of cytolytic T cell responses to tumors and the development of GVHD, and transgenic overexpression of TNFSF14 / LIGHT / CD258 within T cells leads to T cell expansion and causes various severe autoimmune diseases.

HVEM & LIGHT Immune Checkpoint Pathway: Reference

Qunrui Ye et al. Modulation of LIGHT-HVEM Costimulation Prolongs Cardiac Allograft Survival. J Exp Med. 2002 Mar 18; 195(6): 795–800.